Reply  by DiMarco, John P. & Lerman, Bruce B.
The letter by Mini and asroc~aw~ illustrates come of Ihe pmblemr 
associated wdh trials using a “ew anfiarrhythmic drug. Studies such 
as they propose may pro”ldc useful data but ur.kTtunately C?mOl 
safely be camed out m patients with lifc.thrcatcnins nurloined 
venrncular tacbyarrhylhmia. Exfrapolati”” of safety and eficacy 
da& from patients with asymptomatic arrhythmia to patients with 
sustained arrhylhmia is no! always accoralr because %mpc”tic 
plasma concentn,ions may direr between Ibe IWO groups (1, and 
padents in the latter group are oflen more likely to develop cardiac 
and en,razanliac advcrrc e&cl\ a, ellecdve plasma E”“cC”trati”“S 
(21. 
Several other queslions raised by Latini et al. should also be 
addrcrrcd. Although Ihe minimal follow-up in our sludy war only I 
month, ar stated in “or Methods section, only patients who died or 
who had the drug diseondnued because of adverse effects were 
followed up for <I4 months on amiodamne Lhempy. We agree lhat 
myocardial drug conccntra~ions may correlale bcttcr wkh ami- 
anhylhmie ectivily than with plasma c”nce”tre.d”nr. be! serial 
cardiac biopsies are a” impractical method by which to guide 
long-lerm outpatient therapy. Therapy was considered ineteclive if 
a symptomatic sourmined lachyarrbythmia occurred afierthe loading 
period. The plarma c”ncenlr.,tion at or nearest lhat event was used 
for aoalvsis. 
Ideai studies on new antiarrhythmic dmgr with unusual pharma- 
cokinetics lbke amiodarone are difficull lo design. Although all 
Selection and Outcome of Patients Referred 
for Cardiac Transplantation 
Evana and Mater (11 present a” interesting analysts “fthe results of 
referral “fpatiems 1” vari”“~ medical ccnlcrs for cardiac tmorplan- 
tation. One of the more wkmg findings m their study wes the 
difference between centers in the percentage ofpalientraccepted for 
transplantation (69.1% ~1 the Universily of Pittsburgh wsos 26.2% 
“1 Sanford University). I” their discuaaio” of these findings. the 
authors fat! to pom, out probably the roost salienl expkmalion for 
there differences, namely. the mechanism for deciding whether a 
patient is acceplable for cardiac transplanle.ti”n at a give” ioslitu- 
lion. It would seem quite likely that rhe pcrccnlagc of palienta 
accepted would be higher at a” instilotion where. for example. the 
cardiac surge”” receiving the referral war the only individual 
deciding on the suitability “f~ransplantot~on. es opposed 1” a cemet 
where thic decision is the joiot responsibilily of members of a 
comodtlee comprising cardiologist% su:ge”“s and other medical 
specialists. It would be of importaocc 1” know if the authors have 
any dota pertaining 1” Ihe method of ?elecli”n RI Ihe iostilwioos 
studied. 
Engel raises a” important issue concerning the selection of heart 
transplant recipients. He su~ests that programs that admit candi- 
dales for trdnsolantation solclv on the basis of the iudemeot of” 
cardiac surgeon are likely to have a higher acceplaoc~ race than that 
of centers where a team of surgeons. physicians and olher medical 
specialists determines the soitabiliry of” patient referred for cxdiac 
tr*“sphnlali”n. 
This hypothesis is not borne out by the dale amassed during the 
conduct ofthe National Heart Transplantation Study II). In Volume 
I of the study we describe 81 length each of the transplos&dion 
centers that participated in the study. It is noteworthy that both the 
Stanford University Medical Center and the University of Pitts- 
burgh follow what might be referred to as a “team approach” to 
patient selection. To my knowledge, the majority of cardiac fraos- 
planteli”” programs in the U.S. follow the team approach when 
selecling llsnsplanf candidates. This is particularly imponant given 
problems associated with Le management of the patient after 
transpkmtalion. Only in potentially dire circumstances might the 
need for a team evaluation be obviated by a” aggressive surge”“. 
How frequently such circumstances may arise is difficuli to iudae 
based on our data 
In eoncloei”“, Lerefow. we have ““evidence 1” wppw Engel’s 
hypothesis. “or do we know of the availability of such data. We 
remain convinced that the patient selecli”” ~~feTi”~f~~“spl”“tii”” 
lenm chooses Lo adhere Lo are the major delerminanls of the case 
mix of patients who become candidawe for transplantation in 
individual programs. Over the coarse of ““I study wch criteria 
changed and it appeared that the Pittsburgh program was somewhat 
morelenienltha” LheSlanford programinthe selection”ftnnsplant 
recipients. Also. because the team appmach to patient selection was 
a constam rather than a variable in “or study. there was no need to 
examine it w an independent predictor of patient ““~come, akhough 
it could be argued that Ihe quality of team member interncoon may 
vary across programs. 
